Rare Diseases Treatment Market (By Therapeutic Area: Cancer, Musculoskeletal Conditions; By Route of Administration; By Drug Type; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Rare Diseases Treatment Market 

5.1. COVID-19 Landscape: Rare Diseases Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Rare Diseases Treatment Market, By Therapeutic Area

8.1. Rare Diseases Treatment Market, by Therapeutic Area, 2022-2030

8.1.1. Cancer

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Neurological Conditions

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Cardiovascular Conditions

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Musculoskeletal Conditions

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Hematologic Disorders

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Infectious Diseases

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Metabolic disorders

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Endocrine disorders

8.1.8.1. Market Revenue and Forecast (2017-2030)

8.1.9. Others

8.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Rare Diseases Treatment Market, By Route of Administration

9.1. Rare Diseases Treatment Market, by Route of Administration e, 2022-2030

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Injectable

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Rare Diseases Treatment Market, By Drug Type 

10.1. Rare Diseases Treatment Market, by Drug Type, 2022-2030

10.1.1. Biologics

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Biosimilar

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Small Molecule

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Rare Diseases Treatment Market, By Distribution Channel 

11.1. Rare Diseases Treatment Market, by Distribution Channel, 2022-2030

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Specialty Pharmacy

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Rare Diseases Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. F. Hoffmann-La Roche Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Pfizer, Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. PTC Therapeutics

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. AstraZeneca

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Novartis AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Takeda Pharmaceutical Company

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. AbbVie Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Merck & Co. Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Bristol Myers Squibb

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms